Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPN171H Phase Ib in PAH
NCT05948644Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Apr 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TPN171H in pulmonary arterial hypertension (PAH), sponsored by Vigonvita Life Sciences. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 2 years, Q-T interval at 2 years and 8 more. Started Apr 2019; status: completed.
02
Drugs
TPN171H
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05948644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948644.